Tel Aviv, Israel and Danvers, MA – November 20, 2018 – MaxQ AI , a clinical diagnostics intelligence platform company, and NeuroLogica, a subsidiary of Samsung Electronics Co., Ltd., a leader in medical imaging technology, today announced a distribution agreement to integrate MaxQ AI’s artificial intelligence (AI) software with Samsung NeuroLogica’s medical imaging hardware in the United States and European Union acute care marketplace. As part of this agreement, Samsung NeuroLogica will be able enhance its offerings with MaxQ AI’s Accipio Ix, part of MaxQ AI’s unique ACCIPIO INSIGHT™ intracranial hemorrhage platform, which supports acute care physicians by identifying patients with suspected intracranial hemorrhage, and prioritizing those patients, using adult non-contrast head computed tomography (CT) imaging.
“Following the recent FDA clearance and CE Mark approval of Accipio Ix, our expanded partnership with Samsung NeuroLogica will further accelerate the commercialization of our AI powered solutions for the acute care market,” said Chris Schnee, SVP Commercial Operations for MaxQ AI. “Designed for seamless integration into CT and PACS systems, our platform coupled with the unique mobile CT offering of Samsung NeuroLogica, will bring critical life-saving decisions directly to patients in Mobile Stroke Units and to the bed-side of acute care hospital departments. Intelligent imaging, empowering physicians to make more accurate assessments in any location, at any time.”
Samsung NeuroLogica’s U.S. and E.U. sales teams will now offer Accipio Ix solution as an additional tool for its OmniTom® mobile 16-slice CT scanner – the world’s first medical device delivering high-quality non-contrast CT scans at the patients’ bedside with omni-directional wheels. In addition, MaxQ’s AI solutions will be available for integration into Samsung NeuroLogica’s U.S. and E.U. mobile stroke unit (MSU), a specialized ambulance or other emergency vehicle that is equipped with a CereTom® CT (computed tomography) scanner. The mobile unit with diagnostic CT imaging capabilities is designed to allow the team onboard to quickly assess whether a patient is having a stroke caused by hemorrhage.
“We are honored to partner with MaxQ AI and their flagship product Accipio Ix. AI is an exciting development in healthcare, and through our joint efforts, we are working to improve diagnostic accuracy and reduce time to treatment for stroke,” said David Webster, Chief Operating Officer of NeuroLogica. “AI has the potential to revolutionize diagnostics, and this collaboration will bring that potential into the patient’s room through our point of care CT systems.”
A stroke occurs when blood flow to the brain is interrupted by a blockage or a rupture in an artery, depriving brain tissue of oxygen. Stroke is the fifth leading cause of death in the United States and a leading cause of disability. According to the CDC, close to 800,000 Americans suffer a stroke each year. Treatment can be delayed after a suspected stroke patient arrives in the emergency department because of the time needed to determine the best treatment pathway.
Accipio Ix, which has received both FDA clearance and CE Mark approval, leverages artificial intelligence technology to automatically analyze non-contrast head CT images. The AI-powered Accipio Ix, part of MaxQ AI’s unique ACCIPIO INSIGHT™ platform, is designed to be highly sensitive to the presence of ICH, identifying and prioritizing patients with a brain bleed for the treating physician. It provides a capability for rapid escalation and prioritization of the patient and can be natively integrated into CT and PACS systems using the imaging industry-standard DICOM, installed both on-premise and cloud-capable.
MaxQ AI will be demonstrating Accipio Ix – along with additional ACCIPIO platform solutions in development – during the Radiological Society of North America (RSNA) 2018 Annual Meeting in Chicago (Booth #6161 in the North Hall).
About MaxQ AI
MaxQ AI is at the forefront of transforming healthcare by empowering physicians to provide ‘smarter care’ with artificial intelligence (AI) clinical insights. Based in Tel Aviv, Israel and Andover, MA, our team of deep learning and machine vision experts develop clinical diagnostic intelligent software solutions that enable timely and more accurate diagnosis. Working with world-class clinical and industry partners, we are raising the level of acute care in hospitals around the world to improve patient outcomes and lower costs. To learn more, please visit www.maxq.ai or follow us on Twitter and LinkedIn.
NeuroLogica, the healthcare subsidiary of Samsung Electronics Co., Ltd., develops, manufactures, and markets innovative imaging technologies and is committed to delivering fast, easy and accurate diagnostic solutions to healthcare providers. NeuroLogica, the global corporate headquarters and manufacturer of Samsung computed tomography, is also the US headquarters for sales, marketing and distribution of all Samsung digital radiography and ultrasound systems. NeuroLogica’s growing portfolio of advanced medical technologies are used worldwide in leading healthcare institutions helping providers enhance patient care, improve patient satisfaction, and increase workflow efficiency. For more information, please visit www.NeuroLogica.com.
For MaxQ AI:
For Samsung NeuroLogica: